The cellular protein level of parkin is regulated by its ubiquitin-like domain

被引:37
作者
Finney, N [1 ]
Walther, F [1 ]
Mantel, PY [1 ]
Stauffer, D [1 ]
Rovelli, G [1 ]
Dev, KK [1 ]
机构
[1] Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland
关键词
D O I
10.1074/jbc.C300051200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkin is a ubiquitin-protein isopeptide ligase (E3) involved in ubiquitin/proteasome-mediated protein degradation. Mutations in the parkin gene cause a loss-of-function and/or alter protein levels of parkin. As a result, the toxic build-up of parkin substrates is thought to lead to autosomal recessive juvenile Parkinsonism. To identify a role for the ubiquitin-like domain (ULD) of parkin, we created a number of hemagglutinin (HA)tagged parkin constructs using mutational and structural information. Western blotting and immunocytochemistry showed a much stronger expression level for RA-parkin residues 77-465 (without ULD) than HA-par-kin full-length (with ULD). The deletion of ULD in Drosophila parkin also caused a sharp increase in expression of the truncated form, suggesting that the function of the ULD of parkin is conserved across species. By progressive deletion analysis of parkin ULD, we found that residues 1-6 of human parkin play a crucial role in controlling the expression levels of this gene. HA-parkin residues 77-465 showed ubiquitination in vivo, demonstrating that the ULD is not critical for parkin auto-ubiquitination; ubiquitination seemed to cluster on the central domain of parkin (residues 77-313). These effects were specific for the ULD of parkin and not transfection-, toxic-, epitope tag-, and/or vector-dependent. Taken together, these data suggest that the 76 most NH2-terminal residues (ULD) dramatically regulate the protein levels of parkin.
引用
收藏
页码:16054 / 16058
页数:5
相关论文
共 30 条
[1]   A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe [J].
Abbas, N ;
Lücking, CB ;
Ricard, S ;
Dürr, A ;
Bonifati, V ;
De Michele, G ;
Bouley, S ;
Vaughan, JR ;
Gasser, T ;
Marconi, R ;
Broussolle, E ;
Brefel-Courbon, C ;
Harhangi, BS ;
Oostra, AB ;
Fabrizio, E ;
Böhme, GA ;
Pradier, L ;
Wood, NW ;
Filla, A ;
Meco, G ;
Denefle, P ;
Agid, Y ;
Brice, A .
HUMAN MOLECULAR GENETICS, 1999, 8 (04) :567-574
[2]   Features of the Parkin/ariadne-like ubiquitin ligase, HHARI, that regulate its interaction with the ubiquitin-conjugating enzyme, UbcH7 [J].
Ardley, HC ;
Tan, NGS ;
Rose, SA ;
Markham, AF ;
Robinson, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (22) :19640-19647
[3]   Parkin is metabolized by the ubiquitin/proteosome system [J].
Choi, P ;
Ostrerova-Golts, N ;
Sparkman, D ;
Cochran, E ;
Lee, JM ;
Wolozin, B .
NEUROREPORT, 2000, 11 (12) :2635-2638
[4]  
CHOI P, 2000, SOC NEUR ABSTR, V26
[5]   Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1:: implications for Lewy-body formation in Parkinson disease [J].
Chung, KKK ;
Zhang, Y ;
Lim, KL ;
Tanaka, Y ;
Huang, H ;
Gao, J ;
Ross, CA ;
Dawson, VL ;
Dawson, TM .
NATURE MEDICINE, 2001, 7 (10) :1144-1150
[6]   The protein kinase Cα binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits [J].
Dev, KK ;
Nishimune, A ;
Henley, JM ;
Nakanishi, S .
NEUROPHARMACOLOGY, 1999, 38 (05) :635-644
[7]  
DEV KK, 2003, IN PRESS NEUROPHARMA
[8]   Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain [J].
Fallon, L ;
Moreau, F ;
Croft, BG ;
Labib, N ;
Gu, WJ ;
Fon, EA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (01) :486-491
[9]   Neuroscience - Parkin and its substrates [J].
Haass, C ;
Kahle, PJ .
SCIENCE, 2001, 293 (5528) :224-225
[10]   The ubiquitin system [J].
Hershko, A ;
Ciechanover, A .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :425-479